

23rd March 2020

Outreach from AstraZeneca UK on COVID-19

Dear Healthcare Professional,

We write to you at this unprecedented time to extend AstraZeneca UK's full support and solidarity in the face of the COVID-19 pandemic. This is truly an urgent situation, one to which all members of society, including AstraZeneca, stand as one to overcome this disease afflicting our nation.

Over the past week, we have reached out directly via our oncology/haematology field Medical teams to gain first-hand insight into what is needed on the ground. Members of the healthcare community treating patients with oncology and haematological conditions have informed us on many urgent and anticipated needs:

- where urgent treatment guidance is needed - especially on treatment of patients with chemotherapy, where chair-time in hospital is severely affected with specific concerns surrounding myelosuppressive regimens,
- how many are considering remote/digital means of consultation with patients to reduce patient presence in hospitals,
- how clinical studies currently running will be impacted,
- anticipation of an increased need of ventilators, and many more concerns

At AstraZeneca, we are equally concerned, and we seek to continue our two-way dialogue with you on the needs today and also emerging needs for the NHS.

We are currently in dialogue and working with the Government and the NHS to find out how we can best support our community. On Sunday, 22nd March, Mr Robert Jenrick, Secretary of State for Housing, Communities and Local Government, stated how the Government has identified with the NHS, approximately 1.5 million patients who are vulnerable and amongst these, patients with cancer/haematological conditions who may be immunocompromised. The Government intends to create 'hubs' of local support network for these patients, of which AstraZeneca plans to be committed to support as well.

Over the coming weeks and months, we will work with you to support you to the best of our ability to ensure that patients with oncology and haematological conditions are not denied of medicines and that they are best supported at this critical time. Please contact your local field AZ representative should you wish to feedback to us any needs or insights.

Yours faithfully,



Mohit Manrao,
Oncology Business Unit Director,
AstraZeneca UK



Dr Alan Yong,
Oncology Medical Affairs Head,
AstraZeneca UK

USEFUL RESOURCES & EMERGING GUIDANCE ISSUED ON COVID-19 RELATING TO PATIENTS WITH CANCER

Clinical guide for the management of cancer patients during the coronavirus pandemic:

https://www.england.nhs.uk/coronavirus/wp-content/uploads/sites/52/2020/03/Specialty-guide_Cancer-and-coronavirus_17-March.pdf

British Journal of Haematology, Care of haematology patients in a COVID-19 epidemic:

<https://onlinelibrary.wiley.com/doi/epdf/10.1111/bjh.16620>

NICE Coronavirus (COVID-19) guidelines:

[https://www.nice.org.uk/search?om=\[{%22ndt%22:\[%22Guidance%22\]}\]&ps=15&q=covid&sp=on](https://www.nice.org.uk/search?om=[{%22ndt%22:[%22Guidance%22]}]&ps=15&q=covid&sp=on)

The Lancet COVID-19 Resource Centre:

<https://www.thelancet.com/coronavirus>

FURTHER INFORMATION FROM ASTRAZENECA

Supply

AstraZeneca has business continuity processes in place to ensure that patients continue to receive their medicines. Our business continuity teams are constantly monitoring the situation. We are working with the Department of Health and our suppliers to prepare for any potential further restrictions on movement. If you have any questions on this topic, please contact our Supply Chain team directly on 0800 032 0501 or supply.chain@astrazeneca.com

Medical Information

To access any information you may need about AstraZeneca medicines, please visit our Medical Information website (medicalinformation.astrazeneca.co.uk). In the event that you have any specific medical questions regarding our medicines which cannot be answered through the website then please contact AZ UK Medical Information on 0800 783 0033 or medical.informationUK@astrazeneca.com.